ReP USP - Resultado da busca

Trabalho de evento-resumo periodico
UGT1A1*28 (Gilbert s Syndrome) polymorphism is associated with hyperbilirubinemia in patients with chronic liver diseases (2007)
Souza, M. M. T.; Ono-Nita, S. K.; Pavão-Pereira, F.; Araujo, V. F.; Nogueira, J. A.; Nita, M. E.; Carrilho, Flair José
Source: Clinics. Conference titles: Simpósio "Avanços em Pesquisas Médicas dos Laboratórios de Investigação Médica do HC-FMUSP". Unidade: FM
Subjects: HEPATOPATIAS, DOENÇA CRÔNICA, GENÓTIPOS, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, M. M. T. et al. UGT1A1*28 (Gilbert s Syndrome) polymorphism is associated with hyperbilirubinemia in patients with chronic liver diseases. Clinics. São Paulo: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 20 nov. 2024. , 2007
APA
Souza, M. M. T., Ono-Nita, S. K., Pavão-Pereira, F., Araujo, V. F., Nogueira, J. A., Nita, M. E., & Carrilho, F. J. (2007). UGT1A1*28 (Gilbert s Syndrome) polymorphism is associated with hyperbilirubinemia in patients with chronic liver diseases. Clinics. São Paulo: Faculdade de Medicina, Universidade de São Paulo.
NLM
Souza MMT, Ono-Nita SK, Pavão-Pereira F, Araujo VF, Nogueira JA, Nita ME, Carrilho FJ. UGT1A1*28 (Gilbert s Syndrome) polymorphism is associated with hyperbilirubinemia in patients with chronic liver diseases. Clinics. 2007 ; 62 S93.[citado 2024 nov. 20 ]
Vancouver
Souza MMT, Ono-Nita SK, Pavão-Pereira F, Araujo VF, Nogueira JA, Nita ME, Carrilho FJ. UGT1A1*28 (Gilbert s Syndrome) polymorphism is associated with hyperbilirubinemia in patients with chronic liver diseases. Clinics. 2007 ; 62 S93.[citado 2024 nov. 20 ]
Trabalho de evento-resumo
High dose amantadine triple therapy is ineffective on treating HCV non-responder patients. (2002)
Marques, S. B.; Nita, S. K. Ono; Notaroberto, S.; Carrilho, Flair José; Medeiros Filho, J. E. M.; Tani, C. M.; Oliveira, J. M.; Matielo, C. E. L.; Gonçalves, L. L.; Clemente, C. M.
Conference titles: Therapies for viral hepatitits. Unidade: FM
Assunto: HEPATOPATIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARQUES, S. B. et al. High dose amantadine triple therapy is ineffective on treating HCV non-responder patients. 2002, Anais.. Boston,: Faculdade de Medicina, Universidade de São Paulo, 2002. . Acesso em: 20 nov. 2024.
APA
Marques, S. B., Nita, S. K. O., Notaroberto, S., Carrilho, F. J., Medeiros Filho, J. E. M., Tani, C. M., et al. (2002). High dose amantadine triple therapy is ineffective on treating HCV non-responder patients. In . Boston,: Faculdade de Medicina, Universidade de São Paulo.
NLM
Marques SB, Nita SKO, Notaroberto S, Carrilho FJ, Medeiros Filho JEM, Tani CM, Oliveira JM, Matielo CEL, Gonçalves LL, Clemente CM. High dose amantadine triple therapy is ineffective on treating HCV non-responder patients. 2002 ;[citado 2024 nov. 20 ]
Vancouver
Marques SB, Nita SKO, Notaroberto S, Carrilho FJ, Medeiros Filho JEM, Tani CM, Oliveira JM, Matielo CEL, Gonçalves LL, Clemente CM. High dose amantadine triple therapy is ineffective on treating HCV non-responder patients. 2002 ;[citado 2024 nov. 20 ]
Trabalho de evento-resumo
High resistance to therapy in cirrhotic patients carrying HCV RNA genotype 3. (2002)
Silva, L. C. da; Nita, S. K. Ono; Madruga, C. L.; Carrilho, Flair José; Bassit, L.; Pinho, J. R. R.; Mello, I. M. V. G. C.; Malta, F. M.; Yamaguchi, M.
Conference titles: Therapies for viral hepatitits. Unidade: FM
Subjects: HEPATOPATIAS, RNA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, L. C. da et al. High resistance to therapy in cirrhotic patients carrying HCV RNA genotype 3. 2002, Anais.. Boston,: Faculdade de Medicina, Universidade de São Paulo, 2002. . Acesso em: 20 nov. 2024.
APA
Silva, L. C. da, Nita, S. K. O., Madruga, C. L., Carrilho, F. J., Bassit, L., Pinho, J. R. R., et al. (2002). High resistance to therapy in cirrhotic patients carrying HCV RNA genotype 3. In . Boston,: Faculdade de Medicina, Universidade de São Paulo.
NLM
Silva LC da, Nita SKO, Madruga CL, Carrilho FJ, Bassit L, Pinho JRR, Mello IMVGC, Malta FM, Yamaguchi M. High resistance to therapy in cirrhotic patients carrying HCV RNA genotype 3. 2002 ;[citado 2024 nov. 20 ]
Vancouver
Silva LC da, Nita SKO, Madruga CL, Carrilho FJ, Bassit L, Pinho JRR, Mello IMVGC, Malta FM, Yamaguchi M. High resistance to therapy in cirrhotic patients carrying HCV RNA genotype 3. 2002 ;[citado 2024 nov. 20 ]
Trabalho de evento-resumo periodico
HCV RNA genotype 3 is frequently found among brazilian patients with liver cirrhosis (LC) unresponsive to combined therapy with interferon and ribavirin (IFN+RB) (2002)
Silva, Luiz C. da; Madruga, Carmen L.; Pinho, João Renato R.; Ono-Nita, Suzane K.; Bassit, Leda; Carrilho, Flair José
Source: Hepatology/ Official Journal of the American for the Study of Liver Diseases. Conference titles: AASLD Annual Meeting and Postgraduate Courses. Unidade: FM
Subjects: HEPATOPATIAS, GASTROENTEROLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Luiz C. da et al. HCV RNA genotype 3 is frequently found among brazilian patients with liver cirrhosis (LC) unresponsive to combined therapy with interferon and ribavirin (IFN+RB). Hepatology/ Official Journal of the American for the Study of Liver Diseases. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 20 nov. 2024. , 2002
APA
Silva, L. C. da, Madruga, C. L., Pinho, J. R. R., Ono-Nita, S. K., Bassit, L., & Carrilho, F. J. (2002). HCV RNA genotype 3 is frequently found among brazilian patients with liver cirrhosis (LC) unresponsive to combined therapy with interferon and ribavirin (IFN+RB). Hepatology/ Official Journal of the American for the Study of Liver Diseases. Philadelphia: Faculdade de Medicina, Universidade de São Paulo.
NLM
Silva LC da, Madruga CL, Pinho JRR, Ono-Nita SK, Bassit L, Carrilho FJ. HCV RNA genotype 3 is frequently found among brazilian patients with liver cirrhosis (LC) unresponsive to combined therapy with interferon and ribavirin (IFN+RB). Hepatology/ Official Journal of the American for the Study of Liver Diseases. 2002 ; 36( 4):[citado 2024 nov. 20 ]
Vancouver
Silva LC da, Madruga CL, Pinho JRR, Ono-Nita SK, Bassit L, Carrilho FJ. HCV RNA genotype 3 is frequently found among brazilian patients with liver cirrhosis (LC) unresponsive to combined therapy with interferon and ribavirin (IFN+RB). Hepatology/ Official Journal of the American for the Study of Liver Diseases. 2002 ; 36( 4):[citado 2024 nov. 20 ]
Trabalho de evento-resumo periodico
Variable and unpredictable outcome in chronic hepatitis B (CHB) patients during and after therapy with high daily doses of lamivudine (LAM) (2002)
Silva, Luiz C. da; Pinho, João Renato R.; Ono-Nita, Suzane K.; Carrilho, Flair José
Source: Hepatology/ Official Journal of the American for the Study of Liver Diseases. Conference titles: AASLD Annual Meeting and Postgraduate Courses. Unidade: FM
Subjects: HEPATOPATIAS, GASTROENTEROLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Luiz C. da et al. Variable and unpredictable outcome in chronic hepatitis B (CHB) patients during and after therapy with high daily doses of lamivudine (LAM). Hepatology/ Official Journal of the American for the Study of Liver Diseases. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 20 nov. 2024. , 2002
APA
Silva, L. C. da, Pinho, J. R. R., Ono-Nita, S. K., & Carrilho, F. J. (2002). Variable and unpredictable outcome in chronic hepatitis B (CHB) patients during and after therapy with high daily doses of lamivudine (LAM). Hepatology/ Official Journal of the American for the Study of Liver Diseases. Philadelphia: Faculdade de Medicina, Universidade de São Paulo.
NLM
Silva LC da, Pinho JRR, Ono-Nita SK, Carrilho FJ. Variable and unpredictable outcome in chronic hepatitis B (CHB) patients during and after therapy with high daily doses of lamivudine (LAM). Hepatology/ Official Journal of the American for the Study of Liver Diseases. 2002 ; 36( 4):[citado 2024 nov. 20 ]
Vancouver
Silva LC da, Pinho JRR, Ono-Nita SK, Carrilho FJ. Variable and unpredictable outcome in chronic hepatitis B (CHB) patients during and after therapy with high daily doses of lamivudine (LAM). Hepatology/ Official Journal of the American for the Study of Liver Diseases. 2002 ; 36( 4):[citado 2024 nov. 20 ]
Trabalho de evento-resumo periodico
A twelve-week period of follow-up after an end of treatment response (ETR) to antiviral therapy in patients with chronic hepatitis C (CH-C) is a reliable period to characterize a sustained response (2002)
Silva, Luiz C. da; Medeiros-Filho, Jose Eymard M.; Pinho, João Renato R.; Ono-Nita, Suzane K.; Carrilho, Flair José
Source: Hepatology/ Official Journal of the American for the Study of Liver Diseases. Conference titles: AASLD Annual Meeting and Postgraduate Courses. Unidade: FM
Subjects: HEPATOPATIAS, GASTROENTEROLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Luiz C. da et al. A twelve-week period of follow-up after an end of treatment response (ETR) to antiviral therapy in patients with chronic hepatitis C (CH-C) is a reliable period to characterize a sustained response. Hepatology/ Official Journal of the American for the Study of Liver Diseases. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 20 nov. 2024. , 2002
APA
Silva, L. C. da, Medeiros-Filho, J. E. M., Pinho, J. R. R., Ono-Nita, S. K., & Carrilho, F. J. (2002). A twelve-week period of follow-up after an end of treatment response (ETR) to antiviral therapy in patients with chronic hepatitis C (CH-C) is a reliable period to characterize a sustained response. Hepatology/ Official Journal of the American for the Study of Liver Diseases. Philadelphia: Faculdade de Medicina, Universidade de São Paulo.
NLM
Silva LC da, Medeiros-Filho JEM, Pinho JRR, Ono-Nita SK, Carrilho FJ. A twelve-week period of follow-up after an end of treatment response (ETR) to antiviral therapy in patients with chronic hepatitis C (CH-C) is a reliable period to characterize a sustained response. Hepatology/ Official Journal of the American for the Study of Liver Diseases. 2002 ; 36( 4):[citado 2024 nov. 20 ]
Vancouver
Silva LC da, Medeiros-Filho JEM, Pinho JRR, Ono-Nita SK, Carrilho FJ. A twelve-week period of follow-up after an end of treatment response (ETR) to antiviral therapy in patients with chronic hepatitis C (CH-C) is a reliable period to characterize a sustained response. Hepatology/ Official Journal of the American for the Study of Liver Diseases. 2002 ; 36( 4):[citado 2024 nov. 20 ]

USP Schools

ReP

Filtros

Authors

Subjects